Hemodialysis Versus Peritoneal Dialysis Drug Expenditures: A Comparison Within the Private Insurance Market.

ABSTRACT:

Rationale and objective

Recent initiatives aim to improve patient satisfaction and autonomy by increasing the use of peritoneal dialysis (PD) in the United States. However, limited knowledge is available about the costs of different dialysis modalities, particularly those incurred by private insurers. In this study, we compared the costs of injectable dialysis drugs (and their oral equivalents) paid by insurers between privately insured patients receiving hemodialysis and PD.

Study design

A retrospective cohort study.

Setting and participants

From a private insurance claims database, we identified patients who started receiving PD or in-center hemodialysis between January 1, 2017, and December 31, 2020.

Exposure

Patients started receiving PD.

Outcomes

Av

SUBMITTER: Bhatnagar A 

PROVIDER: S-EPMC10344940 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature